MRK's growing pipeline, acquired assets and new product launches are gaining traction as it builds a diversified growth base ahead of Keytruda's 2028 LOE.

JNJ's diversified portfolio and pipeline strength offer an edge over MRK as both face patent expiration challenges.

In the latest trading session, Johnson & Johnson (JNJ) closed at $267.37, marking a -2.21% move from the previous day.

Johnson & Johnson (JNJ) is back in focus after its stock moved higher following a 6.6% rise in second quarter sales and an improved outlook for 2026. See our latest analysis for Johnson & Johnson. The recent second quarter update and regulatory news around Johnson & Johnson's MONARCH QUEST 3 system have come alongside strong momentum, with a 30 day share price return of 9.88% and an 81.38% total shareholder return over three years. This suggests investors have increasingly rewarded its...

The products meant to offset the KEYTRUDA patent expiry were named, and two were already booking revenue, before the stock moved.

The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its expiring patents will take away.

Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.

Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.

You do not expect a pharmaceutical giant with a $376 billion market cap to put up numbers that make growth investors blush. Yet over the last 12 months, Merck (MRK) handed investors an 80% return, lapping the S&P 500. The apex occurred yesterday, August 19, 2026, when the stock surged to all-time highs.

The stock has stood out while the index has barely moved, but the number that matters for a portfolio is how little of its return comes from the market.

AbbVie's upside case now turns on one pending dosing change for the medicine that supplies close to a third of guided revenue, and management expects it to speed up sales.

Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.

Teva's stock gains reflect stronger branded drug growth, a strengthening pipeline and improving finances, but generics and debt remain key risks.

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%

Retiring at 55 sounds like freedom, but seven years without a paycheck or Social Security creates a funding gap that destroys most portfolios before the first benefit check ever arrives. The yield tier you choose now determines whether you cross that bridge or fall through it.

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%

Johnson & Johnson (NYSE:JNJ) continues to stand out as a dividend stock for investors who value dependable income and a long track record of growth. In April 2026, the company raised its dividend by 3.1%, bringing the quarterly payment to $1.34, or $5.36 a year. It was the company’s 64th consecutive year of dividend increases, […]

J&J raises 2026 outlook after second-quarter sales rise 6.6% to $25.31 billion.

The safest Vanguard funds can help you through a volatile market by adding stability to your portfolio at low cost.

These four low-cost Vanguard dividend and income funds have all earned high praise from Morningstar, and they offer attractive yields.

Johnson & Johnson (NYSE: JNJ) received FDA clearance for its MONARCH QUEST 3 bronchoscopy system, a software update to its robotic assisted bronchoscopy platform. The update introduces AI powered tools for procedure planning and lung nodule segmentation within Johnson & Johnson's MedTech portfolio. The clearance expands Johnson & Johnson's capabilities in minimally invasive diagnostics and treatment in robotic assisted bronchoscopy. New digital ecosystem features are designed to support...

Dividend growth ETFs offer investors a steadily growing stream of passive income and exposure to quality companies.

J&J's immunology and neuroscience businesses are emerging as key growth engines, with new drugs helping to offset Stelara's loss of exclusivity.

Colgate-Palmolive Company (NYSE:CL) is often overlooked when investors discuss established dividend stocks. Names such as Coca-Cola, Procter & Gamble, and Johnson & Johnson tend to dominate those conversations. Colgate has a track record that deserves to be mentioned alongside them. It is a Dividend King, with 63 consecutive years of dividend increases and uninterrupted dividend payments […]

While the market chases momentum trades and AI multiples, a small group of blue-chip dividend compounders has quietly raised its payouts for generations and continues doing so in 2026. These five names carry the streaks, the cash flow, and the brand moats to keep rewarding patient investors well into next year.

Generating $210,000 a year in dividends sounds impossible until you break the portfolio into three distinct yield buckets, each with its own risk profile and capital requirement. The math is brutally simple, but most investors build the wrong blend and wonder why their income stagnates.

The MONARCH platform provides flexible, robotically assisted visualisation and airway access for bronchoscopic procedures.

The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group's fastest-growing performers trading at a middle-of-the-pack multiple rather than the group high.

Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.

The biosimilar drag on Johnson & Johnson stock is shrinking, and the business underneath it is already growing at a double-digit pace.

The yield you chase to replace a salary can quietly destroy the purchasing power you built to protect. Before you settle on a number, understand what the tradeoff between yield and dividend growth actually costs you over a decade.

Pharma's 2026 recovery puts Bayer, Eli Lilly and Johnson & Johnson in focus as innovation and M&A offset pricing and patent headwinds.

Some companies have handed investors a bigger paycheck every single year for more than six decades, surviving every recession and rate shock along the way. Five of them look particularly compelling right now, and one trades at a price not seen in over a year.

Johnson & Johnson shares have quietly delivered a huge gain in 2026 so far, up more than 25%. The gain has similarly shown strong outperformance relative to the S&P 500, with recent results driving positive momentum post-earnings.

AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

Johnson & Johnson has delivered a 68.9% total return over the past 5 years, yet its valuation picture is split, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while market multiples lean the other way. Over 5 years, Johnson & Johnson has returned 68.9%, which puts the recent share price near the upper end of its longer term journey. Pipeline progress in areas such as major depressive disorder therapies and new medical technologies like surgical robotics can...

AbbVie's neuroscience franchise posts strong first-half growth, with Vyalev accelerating and tavapadon poised to add another potential growth driver.

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

Fifty-plus years of unbroken dividend raises sounds like a floor, but not every Dividend King deserves a permanent seat in your portfolio right now. Five do, and one of them is actually trading at a discount that long-term income investors rarely get handed.

Medicare's IRMAA surcharge punishes a single dollar of overage with a full bracket jump and no phase-in, yet some retirees collect six figures annually and never trigger it. The strategy depends on how income is classified, not how much arrives.

The World Health Organization projects that the share of the world’s population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging […]

Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes.

Rolling $880,000 into a self-directed IRA sounds like a clean break from the 9-to-5, but generating $5,200 a month from that balance forces a choice between safety and survival that most retirement calculators never show you.

The pharmaceutical giant just increased its dividend by 3.1%, now paying $5.36 a share annually.

AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.

Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. See our latest analysis for Intuitive Surgical. The Q2 surprise arrives after a tough stretch for Intuitive Surgical, with the share price down 28.6% year to date and the 1 year total shareholder return declining 16.1%. The recent 7 day...

The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.